| Ataxin-1 | |
|---|---|
| Protein Name | Ataxin-1 |
| Gene | ATXN1 |
| UniProt | P54253 |
| Protein Class | Nuclear protein; transcriptional co-regulator |
| Localization | Nucleus; nuclear inclusions in disease |
| Major Pathway | RNA Metabolism; Transcriptional Regulation |
Ataxin-1 (encoded by the ATXN1 gene) is a 815 amino acid nuclear protein that plays critical roles in transcriptional regulation and RNA processing. Pathogenic CAG repeat expansions in the ATXN1 gene cause spinocerebellar ataxia type 1 (SCA1), characterized by progressive cerebellar ataxia, dysarthria, and eventual bulbar dysfunction[1][2].
Beyond its well-characterized role in SCA1, ataxin-1 has been implicated in the pathogenesis of other neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, where it may contribute to protein aggregation, transcriptional dysregulation, and neuronal vulnerability[3].
Ataxin-1 contains several functionally distinct domains[1:1][4]:
Ataxin-1 functions as a nuclear transcriptional regulator[5][6]:
The protein is involved in RNA metabolism:
In SCA1, pathogenic CAG repeat expansions result in an expanded polyglutamine tract[1:2][7]:
Ataxin-1 is expressed primarily in neural tissues[2:1]:
Under normal conditions[4:1][8]:
The hallmark of SCA1 pathology is the formation of nuclear inclusions[9][4:2]:
Ataxin-1 inclusions sequester transcription factors[5:1][10]:
The primary pathology in SCA1 involves Purkinje cell loss[11][12]:
Ataxin-1 has been implicated in AD pathogenesis[3:1]:
Evidence for ataxin-1 involvement in PD[3:2]:
Several therapeutic modalities are being explored[13][@chou2008][14]:
Several SCA1 mouse models have been developed[15][13:1][7:1]:
Ataxin-1 interacts with several proteins[5:2][3:3]:
| Partner | Interaction | Function |
|---|---|---|
| RORα | Direct | Transcriptional co-repressor |
| CtBP | Direct | Co-repressor complex |
| Axin | Direct | Wnt signaling |
| Polyglutamine proteins | Indirect | Aggregation propensity |
| 14-3-3 proteins | Phospho-dependent | Subcellular localization |
Orr HT, et al. Spinocerebellar ataxia type 1: from pathogenesis to therapeutic interventions. Cell. 2002. ↩︎ ↩︎ ↩︎
Matilla A, et al. The nuclear蛋白 ataxin-1: implications for cerebellar degeneration. Trends in Neurosciences. 1998. ↩︎ ↩︎
Alves-Ribeiro M, et al. Ataxin-1 function beyond SCA1: implications for neurodegeneration. Cellular and Molecular Neurobiology. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Klement IA, et al. Ataxin-1 nuclear localization and aggregation in SCA1. Cell. 1998. ↩︎ ↩︎ ↩︎
Gao RF, et al. Ataxin-1 interacts with the co-repressor CtBP in cerebellar degeneration. Human Molecular Genetics. 2002. ↩︎ ↩︎ ↩︎
Cvetanovic M, et al. Ataxin-1 mediates neuroprotection through transcriptional regulation. Neurobiology of Disease. 2012. ↩︎
Zu T, et al. Recovery of polyglutamine-induced neurological dysfunction in SCA1. Science. 2003. ↩︎ ↩︎
Stuart J, et al. Nuclear accumulation of ataxin-1 in SCA1 is age-dependent. Neurobiology of Disease. 2007. ↩︎
Skinner PJ, et al. Ataxin-1 protein forms nuclear inclusions in a SCA1 mouse model. Nature. 1997. ↩︎
Serra HG, et al. Gene profiling links SCA1 pathophysiology to oxidative stress. Human Molecular Genetics. 2006. ↩︎
Cheng Y, et al. Neuroanatomic alterations in SCA1 mice reveal therapeutic targets. Brain Research. 2003. ↩︎
Bowman AB, et al. Neuronal dysfunction in SCA1: beyond the cerebellum. Trends in Neurosciences. 2007. ↩︎
Emamian ES, et al. Dimebolin improves motor and cognitive deficits in SCA1 transgenic mice. Brain Research. 2003. ↩︎ ↩︎
Inverma L, et al. Therapeutic approaches for SCA1: current status and future directions. Journal of Neurology. 2013. ↩︎
Koob MD, et al. An 8-kb BAC transgene recapitulates SCA1 neuropathology in mice. Human Molecular Genetics. 1999. ↩︎